Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | INSR | P06213 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 3/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099977 | 0.88 | ALK (0.53) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL4096101 | 0.84 | EGFR (0.54) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL4093651 | 0.84 | INSR (0.52) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL4104371 | 0.82 | ALK (0.53) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL375536 | 0.79 | ALK (0.53) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL13849413 | 0.79 | ALK (0.57) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL13849428 | 0.78 | EGFR (0.53) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL12311877 | 0.76 | ULK1 (0.61) | ALKEGFRINSRIGF1RMAPK9 | |
| SCHEMBL375776 | 0.76 | ULK1 (0.53) | ALKINSRIGF1RMAPK9MAPK10 | |
| SCHEMBL13849411 | 0.76 | INSR (0.56) | ALKEGFRINSRIGF1RMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ALK 2060/4885EGFR 3112/4885INSR 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.